2009
Evaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF/MS procedure
Hawke D, Mazouni C, André F, Baggerly K, Baggerly K, Tsavachidis S, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF/MS procedure. Journal Of Clinical Oncology 2009, 27: e22072-e22072. DOI: 10.1200/jco.2009.27.15_suppl.e22072.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBreast cancerPrimary chemotherapyHER2-positive patientsPathological complete responseBreast cancer cohortPositive patientsComplete responseUnnecessary toxicityResidual diseaseTumor responseCancer cohortBlood samplesChemotherapyResponse rateTreatment cyclesPosttreatment samplesCancerSerum samplesRD groupSignificant financial relationshipPatientsProfile changesRespondersTotal
2007
Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients
Desmedt C, André F, Azambuja E, Haibe-Kains B, Larsimont D, D'Hondt V, Di Leo A, Piccart M, Pusztai L, Sotiriou C. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients. Journal Of Clinical Oncology 2007, 25: 10564-10564. DOI: 10.1200/jco.2007.25.18_suppl.10564.Peer-Reviewed Original ResearchPathological complete responseBreast cancerLarge seriesEstrogen receptor-negative breast cancer patientsNegative breast cancer patientsAffymetrix gene expression profilesAnthracycline-based therapyER-negative patientsBreast cancer patientsGene expression profilesOvarian suppressionComplete responseP53 signaturePrognostic valueCancer patientsSubgroup analysisMD AndersonStudent's t-test analysisTOP trialBC diseaseExpression profilesGene expression profilingTherapySignificant financial relationshipPatients